GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBF) » Definitions » EV-to-EBITDA

Medivir AB (Medivir AB) EV-to-EBITDA : -3.62 (As of Apr. 30, 2024)


View and export this data going back to . Start your Free Trial

What is Medivir AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medivir AB's enterprise value is $28.98 Mil. Medivir AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.99 Mil. Therefore, Medivir AB's EV-to-EBITDA for today is -3.62.

The historical rank and industry rank for Medivir AB's EV-to-EBITDA or its related term are showing as below:

MVRBF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -68.14   Med: -2.3   Max: 111.49
Current: -2.43

During the past 13 years, the highest EV-to-EBITDA of Medivir AB was 111.49. The lowest was -68.14. And the median was -2.30.

MVRBF's EV-to-EBITDA is ranked worse than
100% of 469 companies
in the Biotechnology industry
Industry Median: 9.09 vs MVRBF: -2.43

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-30), Medivir AB's stock price is $0.82. Medivir AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.032. Therefore, Medivir AB's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Medivir AB EV-to-EBITDA Historical Data

The historical data trend for Medivir AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB EV-to-EBITDA Chart

Medivir AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.83 -3.93 -7.06 -5.27 -1.66

Medivir AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.27 -4.75 -4.09 -3.84 -1.66

Competitive Comparison of Medivir AB's EV-to-EBITDA

For the Biotechnology subindustry, Medivir AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Medivir AB's EV-to-EBITDA falls into.



Medivir AB EV-to-EBITDA Calculation

Medivir AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=28.975/-7.994
=-3.62

Medivir AB's current Enterprise Value is $28.98 Mil.
Medivir AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medivir AB  (OTCPK:MVRBF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Medivir AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.82/-0.032
=At Loss

Medivir AB's share price for today is $0.82.
Medivir AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.032.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Medivir AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Medivir AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Medivir AB (Medivir AB) Business Description

Traded in Other Exchanges
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.